SSG
JANX icon

Summit Securities Group’s Janux Therapeutics JANX Stock Holding History

Summit Securities Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-700
Closed -$32K – 770
2024
Q3 		$32K Hold
700
– – 0.01% 275
2024
Q2 		$29K Buy
+700
New +$32.9K 0.01% 346

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Summit Securities Group's JANX Position: Q4 2024 in Review

Summit Securities Group sold out of Janux Therapeutics (JANX) in Q4 2024, closing a stake of 700 shares — an estimated $32K sold.

Summit Securities Group first reported a position in JANX in Q2 2024 and held it in 2 quarters. The position peaked at $32K in Q3 2024. 216 funds tracked by Wall St. Rank hold JANX as of Q4 2024.

  • Summit Securities Group reported no remaining Janux Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Summit Securities Group sold 700 Janux Therapeutics shares in Q4 2024, an estimated $32K.
  • Summit Securities Group first reported a position in Janux Therapeutics in Q2 2024 and held it in 2 quarters.
  • Summit Securities Group's Janux Therapeutics position peaked at $32K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2024.

Based on Summit Securities Group's 13F filing for Q4 2024, filed 12 Feb 2025.